These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16396066)

  • 1. Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
    Daniel OJ; Krain AB; Ogun SA; Odusoga OL; Boyle BA
    J Natl Med Assoc; 2005 Dec; 97(12):1719-21. PubMed ID: 16396066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
    Bourezane Y; Salard D; Hoen B; Vandel S; Drobacheff C; Laurent R
    Clin Infect Dis; 1998 Nov; 27(5):1321-2. PubMed ID: 9827291
    [No Abstract]   [Full Text] [Related]  

  • 3. Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
    Santos RP; Ramilo O; Barton T
    Pediatr Infect Dis J; 2007 Nov; 26(11):1053-6. PubMed ID: 17984815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
    Soriano V; Dona C; Barreiro P; González-Lahoz J
    AIDS; 2000 Jul; 14(11):1672-3. PubMed ID: 10983663
    [No Abstract]   [Full Text] [Related]  

  • 5. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
    Antinori A; Baldini F; Girardi E; Cingolani A; Zaccarelli M; Di Giambenedetto S; Barracchini A; De Longis P; Murri R; Tozzi V; Ammassari A; Rizzo MG; Ippolito G; De Luca A
    AIDS; 2001 Aug; 15(12):1579-81. PubMed ID: 11504993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
    Manosuthi W; Thongyen S; Chumpathat N; Muangchana K; Sungkanuparph S
    HIV Med; 2006 Sep; 7(6):378-82. PubMed ID: 16903982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
    Steel-Duncan JC; Pierre R; Gabay L; Christie CD
    West Indian Med J; 2004 Oct; 53(5):356-8. PubMed ID: 15675504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Desensitization to Nevirapine.
    TreatmentUpdate; 1999 Nov; 11(8):5. PubMed ID: 11367044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex differences in nevirapine rash.
    Bersoff-Matcha SJ; Miller WC; Aberg JA; van Der Horst C; Hamrick HJ; Powderly WG; Mundy LM
    Clin Infect Dis; 2001 Jan; 32(1):124-9. PubMed ID: 11118391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
    Lackmann GM; Schmidt B; Niehues T
    Hautarzt; 2003 Aug; 54(8):765-6. PubMed ID: 12942192
    [No Abstract]   [Full Text] [Related]  

  • 11. Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature.
    Cattelan AM; Trevenzoli M; Sasset L; Sgarabotto D; Lanzafame M; Meneghetti F
    J Infect; 2001 Nov; 43(4):246-9. PubMed ID: 11869062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.
    Antón P; Soriano V; Jiménez-Nácher I; Rodriguez-Rosado R; Dona MC; Barreiro PM; González-Lahoz J
    AIDS; 1999 Mar; 13(4):524-5. PubMed ID: 10197383
    [No Abstract]   [Full Text] [Related]  

  • 13. Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
    Peters PJ; Stringer J; McConnell MS; Kiarie J; Ratanasuwan W; Intalapaporn P; Potter D; Mutsotso W; Zulu I; Borkowf CB; Bolu O; Brooks JT; Weidle PJ
    HIV Med; 2010 Nov; 11(10):650-60. PubMed ID: 20659176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High incidence of nevirapine-associated rash in HIV-infected Chinese.
    Ho TT; Wong KH; Chan KC; Lee SS
    AIDS; 1998 Oct; 12(15):2082-3. PubMed ID: 9814883
    [No Abstract]   [Full Text] [Related]  

  • 15. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
    van Griensven J; Zachariah R; Rasschaert F; Mugabo J; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
    Zhou J; Phanupak P; Kiertiburanakul S; Ditangco R; Kamarulzaman A; Pujary S;
    J Acquir Immune Defic Syndr; 2006 Dec; 43(4):501-3. PubMed ID: 17099317
    [No Abstract]   [Full Text] [Related]  

  • 18. [Cutaneous, hepatic and hematologic manifestations due to nevirapine: DRESS syndrome?].
    Sissoko D; Ajana F; de la Tribonnière X; Baclet V; Mouton Y
    Presse Med; 2000 May 27-Jun 3; 29(19):1041-2. PubMed ID: 10874910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence and risk factors for nevirapine-associated rash.
    de Maat MM; ter Heine R; Mulder JW; Meenhorst PL; Mairuhu AT; van Gorp EC; Huitema AD; Beijnen JH
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):457-62. PubMed ID: 12920493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine-induced resistance is a problem.
    S Afr Med J; 2004 May; 94(5):338. PubMed ID: 15211947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.